ArticleMedical oncology (Northwood, London, England)2011
May metaplastic breast carcinomas be actually basal-like carcinoma? Further evidence study with its ultrastructure and survival analysis.
Article in Medical oncology (Northwood, London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Metaplastic breast cancer with chondrosarcomatous differentiation combined with concurrent bilateral breast cancer: A case report.World journal of clinical cases · 2022Article
- A Case Report of Targeted Therapy with Anlotinib in a Patient with Advanced Breast Metaplastic Carcinoma.OncoTargets and therapy · 2021Article
- Metaplastic carcinoma of the breast: an immunohistochemical study.Diagnostic pathology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metaplastic breast carcinoma (MBC) encompasses a heterogeneous group of tumors. Based upon the microarray of MBCs, these tumors showed features of basal-like carcinoma and myoepithelial differentiation. However, MBCs entity still remained unclear. So we performed a systematic research to explicit metaplastic breast carcinomas further. A panel of ER, PR, HER-2, CK5/6, CK14, P63 and EGFR were prepared for detection of MBCs, and fluorescence in situ hybridization for HER-2 gene amplification and ultrastructure observation were also performed. Sensitiveness between CK5/6 and other antibodies in diagnosis was analysed, and survival analysis was also carried out. ER, PR and HER-2 were negative. CK5/6 (12/12), CK14 (9/12), EGFR (10/12) and P63 (8/12) were positive. FISH for HER-2 displayed no amplification (ratio values < 1.8). Ultrastructure showed tonofibrils, thin filament and dense body in the cytoplasm. Significant statistical differences were detected between groups (F = 8.080, P = 0.000) of score of CK5/6, CK14, P63 and EGFR. Significant statistical differences were also detected between age and lymph node involvement and survival (χ(2) = 10.835, P = 0.004). MBCs may be actually basal-like carcinomas. In the diagnosis of MBCs, CK5/6, CK14, P63 and EGFR may be effective and CK5/6 may be more sensitive than CK14 and P63. Survival of MBCs may be associated with age and lymph node involvement. However, given the limitations of our research accumulated cases, prospective clinicopathologic studies are needed to further elucidate MBCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.